SEC Comment Letter 0000000000-23-010616 to Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc.
Date: Sept. 26, 2023 · CIK: 0001873835 · Accession: 0000000000-23-010616
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274684
Letter
United States securities and exchange commission logo September 26, 2023 Gabriel Morris Chief Financial Officer Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064 Re:Immix Biopharma, Inc. Registration Statement on Form S-3 Filed September 25, 2023 File No. 333-274684 Dear Gabriel Morris: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika N. Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Melanie Levy
Show Raw Text
United States securities and exchange commission logo
September 26, 2023
Gabriel Morris
Chief Financial Officer
Immix Biopharma, Inc.
11400 West Olympic Blvd., Suite 200
Los Angeles, CA 90064
Re:Immix Biopharma, Inc.
Registration Statement on Form S-3
Filed September 25, 2023
File No. 333-274684
Dear Gabriel Morris:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika N. Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Melanie Levy